# APPROACH TO THE PATIENT WITH DYSLIPIDEMIA

**Kenneth R Feingold MD**, Emeritus Professor of Medicine, University of California- San Francisco. Kenneth.feingold@ucsf.edu

**Updated June 25, 2025**

## ABSTRACT

In evaluating a patient with dyslipidemia, the initial step is to decide which particular lipid/lipoprotein abnormalities need to be evaluated and whether they need treatment. These disorders can be divided into elevations of LDL-C, TGs, non-HDL-C, and Lp(a) and decreases in plasma HDL-C. Frequently a patient can have multiple lipid/lipoprotein abnormalities. The next step is to rule out secondary causes that could account for the abnormal lipid/lipoprotein levels. These secondary causes can be due to diet, various disease states, or drug therapy. One should be suspicious of a secondary cause if a patient suddenly develops a lipid/lipoprotein abnormality or the lipid/lipoprotein profile suddenly worsens. Next one should consider the possibility of a genetic disorder and therefore ask whether relatives have either premature cardiovascular disease, lipid disorders, or are receiving lipid lowering medications. If the TG levels are markedly elevated one should inquire about a family history of pancreatitis. When the lipid/lipoprotein abnormality is markedly abnormal or begins at a young age, the likelihood of a genetic disorder is increased, and the family history assumes even greater importance. In most circumstances a routine lipid panel consisting of plasma TGs, total cholesterol, HDL-C, and calculated LDL-C and non-HDL-C provides sufficient information to appropriately decide on who to treat and the best treatment approach. However, it should be recognized that there are certain situations where more sophisticated and detailed laboratory studies can be helpful. The purpose of treating lipid disorders is to prevent the development of other diseases, particularly cardiovascular disease. Thus, the decision to treat should be based on the risk of hyperlipidemia leading to those medical problems. Several guidelines have been published that discuss cardiovascular risk assessment in detail and provide recommendations on treatment strategies. Additionally, calculators are available on-line to determine an individual patient’s risk of developing cardiovascular disease in the next 10 years or their lifetime risk. In the prevention of cardiovascular disease, the main priority is to lower the LDL-C levels. Reductions in other apolipoprotein B containing lipoproteins may be instituted if LDL-C levels are at goal. Depending on the specific guideline the percent reduction in LDL-C and/or the goal LDL-C will vary depending upon the patient profile. When LDL-C levels are at goal but TG and non-HDL-C levels are still elevated a recent study suggests further treatment with icosapent ethyl may be beneficial. Whether decreasing Lp(a) is beneficial in preventing cardiovascular disease is uncertain and further studies are in progress. Lifestyle changes are the initial treatment but in most patients’ drug therapy will be necessary.

## INTRODUCTION

The initial step is to decide which particular lipid/lipoprotein abnormalities need to be evaluated and whether they need treatment. These disorders can be divided into elevations of LDL-C, triglycerides (TGs), non-HDL-C, and Lp(a), and decreases in HDL-C. An increase in non-HDL-C accompanies an increase in LDL-C and/or TGs levels. Often a patient can have multiple lipid/lipoprotein abnormalities. For example, it is not uncommon for a patient to have high TGs with low HDL-C levels or high LDL-C and high Lp(a) levels.

From a clinical point of view, one is not usually concerned if the LDL-C, Lp(a), or TG levels are low or if the HDL-C level is high. Very low levels of LDL-C and/or TGs suggest the presence of other medical issues such as hyperthyroidism, malabsorption, liver disease, chronic infections, cancer, etc. On rare occasions very low LDL-C levels or TG levels can be due to genetic disorders ([1](#_ENREF_1)). Very high HDL-C levels can also be due to genetic causes ([2](#_ENREF_2)).

## RULE OUT SECONDARY CAUSES

The next step is to rule out secondary causes that could account for the abnormal lipid/lipoprotein levels. These secondary causes can be due to diet, various disease states, or medications. One should be suspicious of a secondary cause if a patient suddenly develops a lipid/lipoprotein abnormality or the lipid/lipoprotein profile suddenly worsens. Patients with genetic abnormalities causing dyslipidemia can have their disorder worsen if they develop secondary causes that further adversely affect lipid/lipoprotein levels.

The key is that if one corrects the secondary cause the lipid/lipoprotein abnormality can often markedly improve or even disappear. For example, hypothyroidism can be accompanied by striking increases in LDL-C levels and the treatment of hypothyroidism can result in a large decrease in LDL-C, often to normal levels ([3](#_ENREF_3)). Likewise, an improvement in glycemic control in a patient with poorly controlled diabetes may result in a large decrease in serum TG levels ([4](#_ENREF_4)). Occasionally, the presence of dyslipidemia leads to the discovery of an unrecognized secondary disorder that requires treatment.

Similarly stopping certain drugs can greatly improve the lipid profile ([5](#_ENREF_5)). For example, in some postmenopausal women with hypertriglyceridemia stopping oral estrogen therapy can result in a marked decrease in TG levels ([3](#_ENREF_3)). The disorders and drugs that cause lipid/lipoprotein abnormalities are shown in tables 1-7. It should be noted that many disorders and drugs can cause multiple lipid abnormalities. The effects of disorders and drugs in an individual patient can vary depending on genetic background and the presence of other disorders and drugs that effect lipid/lipoprotein levels. For an extensive discussion of the secondary disorders that alter lipid and lipoprotein metabolism please refer to the individual Endotext chapters on these disorders. For additional information on the effect of drugs on lipid and lipoprotein metabolism please see the Endotext chapter on this topic ([5](#_ENREF_5)).

|  |
| --- |
| **Table 1. Conditions Associated with an Increase LDL in Cholesterol Levels** |
| Increased intake of saturated or trans fatty acids |
| Ketogenic diet |
| Hypothyroidism  |
| Obstructive liver disease |
| Nephrotic syndrome |
| Pregnancy |
| Growth hormone deficiency |
| Anorexia nervosa |
| Monoclonal gammopathy |
| Cushing’s syndrome |
| Acute intermittent porphyria |
| Hepatoma |

|  |
| --- |
| **Table 2. Drugs That Increase LDL Cholesterol Levels** |
| Cyclosporine and tacrolimus |
| Amiodarone |
| Glucocorticoids |
| Danazol |
| Some progestins |
| Protease inhibitors |
| Anabolic steroids |
| Androgen deprivation therapy |
| Retinoids |
| Thiazide diuretics |
| Loop diuretics |
| Thiazolidinediones |
| SGLT2 inhibitors |
| Mitotane (o,p'DDD) |
| Growth Hormone |
| JAK kinase inhibitors  |

|  |
| --- |
| **Table 3. Conditions Associated with an Increase in TG Levels** |
| Obesity |
| Alcohol intake |
| High simple carbohydrate diet |
| Diabetes |
| Metabolic syndrome |
| Polycystic ovary syndrome |
| Hypothyroidism |
| Chronic renal failure  |
| Nephrotic syndrome |
| Pregnancy |
| Inflammatory diseases (Rheumatoid arthritis, Lupus, psoriasis, etc.) |
| Infections |
| Acute stress (myocardial infarctions, burns, etc.) |
| HIV |
| Cushing’s syndrome |
| Growth hormone deficiency |
| Lipodystrophy |
| Glycogen Storage disease  |
| Acute hepatitis |
| Monoclonal gammopathy |

|  |
| --- |
| **Table 4. Drugs That Increase TG Levels** |
| Alcohol |
| Oral Estrogens |
| Tamoxifen/Raloxifene |
| Glucocorticoids |
| Retinoids |
| Beta blockers |
| Thiazide diuretics |
| Loop diuretics |
| Protease Inhibitors |
| Cyclosporine, sirolimus, and tacrolimus |
| Atypical anti-psychotics  |
| Bile acid sequestrants |
| L-asparaginase |
| Androgen deprivation therapy |
| Cyclophosphamide |
| Alpha-interferon |
| Propofol |

|  |
| --- |
| **Table 5. Conditions Associated with a Decrease in HDL Cholesterol Levels** |
| Marked hypertriglyceridemia |
| Obesity |
| Metabolic syndrome |
| Type 2 diabetes |
| Low fat intake |
| Infection  |
| Inflammation |
| Malignancy |
| Severe liver disease |
| Polycystic ovary syndrome |
| Paraproteinemia (artifact of some assays) |

|  |
| --- |
| **Table 6. Drugs That Decrease HDL Cholesterol Levels** |
| Anabolic steroids |
| Danazol |
| TZD + fibrate (idiosyncratic reaction) |
| Beta-blockers |
| Progestins |
| Atypical anti-psychotics |

|  |
| --- |
| **Table 7. Disorders or Drugs Associated with an Increase in Lp(a) Levels** |
| Chronic Kidney Disease |
| Nephrotic Syndrome |
| Inflammation |
| Hypothyroidism |
| Acromegaly |
| Polycystic ovary syndrome |
| Growth hormone therapy |
| Androgen deprivation therapy |
| Statins |

In a patient with an elevated LDL-C level, one should take a diet history, review the medication list, and check a TSH level to rule out hypothyroidism. Most of the disorders that cause elevations in LDL-C levels, other than hypothyroidism, should be obvious on routine history, physical examination, and laboratory screening. In a patient with an elevated TG level, one should take a diet history and in particular focus on the ingestion of simple sugars and ethanol. One should review the medication list and recognize that many common disease states can adversely impact TG levels including obesity, poorly controlled diabetes, chronic renal failure, HIV, and inflammatory disorders ([4](#_ENREF_4),[6-9](#_ENREF_6)). Weight loss, improvements in glycemic control in patients with diabetes, and a reduction of inflammation can all result in a decrease in TG levels ([4](#_ENREF_4),[7](#_ENREF_7),[8](#_ENREF_8)). In a patient with a low HDL-C level one should review the medication list and diet, recognizing that diets very low in fat can result in low HDL-C levels, which are often accompanied by low LDL-C and TG levels ([10](#_ENREF_10)). In young or very fit males with very low HDL-C levels a careful history directed at anabolic steroid use is essential ([3](#_ENREF_3)).

## THINK ABOUT GENETIC CAUSES

One should always consider the possibility of a genetic disorder and therefore ask whether relatives have either premature cardiovascular disease, lipid disorders, or are taking lipid lowering medications ([11](#_ENREF_11)). If the TG levels are markedly elevated one should inquire about a family history of pancreatitis. When the lipid/lipoprotein abnormality is markedly abnormal or begins at a young age, the likelihood of a genetic disorder is increased, and the family history assumes even greater importance. It is essential to think about the possibility of a genetic disorder because many of the common lipid disorders, such as familial hypercholesterolemia and elevations in Lp(a), have an autosomal codominant genetic transmission and therefore will be present in approximately 50% of family members ([12-16](#_ENREF_12)). The recognition of the possibility of a genetic disorder will lead to screening family members and if abnormalities are found early treatment can be initiated, which may prevent the adverse consequences of hyperlipidemia. The monogenetic disorders that cause elevations in LDL-C and TGs levels and low HDL-C levels are shown in tables 8-11.

|  |
| --- |
| **Table 8. Elevation in LDL Cholesterol (Familial Hypercholesterolemia)** |
| LDL receptor mutations | Autosomal codominant | Approx. 1 in 250 |
| Apolipoprotein B mutations | Autosomal codominant | Approx. 1 in 1000 |
| PCSK9 mutations | Autosomal codominant | rare |
| Autosomal recessive hypercholesterolemia | Autosomal recessive | rare |
| Lysosomal acid lipase deficiency | Autosomal recessive | rare |
| Cholesterol 7 alpha hydroxylase deficiency | Autosomal recessive | rare |
| Sitosterolemia (ABCG5/ABCG8) | Autosomal recessive | rare |

In autosomal codominant disorders heterozygotes have lipid abnormalities approximately half as severe as homozygotes

|  |
| --- |
| **Table 9. Marked Elevations in TGs (Familial Chylomicronemia Syndrome)** |
| Lipoprotein lipase deficiency | Autosomal recessive | rare |
| Apolipoprotein C-II deficiency | Autosomal recessive | rare |
| Apolipoprotein A-V deficiency | Autosomal recessive | rare |
| GPIHBP1 deficiency  | Autosomal recessive | rare |
| Lipase maturation factor 1 deficiency | Autosomal recessive | rare |

|  |
| --- |
| **Table 10. Elevations in TGs and Cholesterol** |
| Familial Dysbetalipoproteinemia | Apo E2/E2, rare mutations in Apo E | 1-5/5000 |

|  |
| --- |
| **Table 11. Decreased HDL Cholesterol** |
| Apolipoprotein A-I deficiency or variants | Autosomal codominant | rare |
| Tangier disease (ABCA1 deficiency) | Autosomal codominant | rare |
| LCAT deficiency | Autosomal codominant | rare |

In autosomal codominant disorders heterozygotes have lipid abnormalities approximately half as severe as homozygotes

Very frequently hypertriglyceridemia and/or hypercholesterolemia are due to polygenic inheritance secondary to combinations of common small effect genes that regulate the production or catabolism of lipoproteins ([17](#_ENREF_17)). Additionally, some individuals who are heterozygotes for the gene abnormalities described in table 9 will have elevated TG levels. In addition, lifestyle, other disease states, and medications can interact with genetic susceptibilities to result in marked dyslipidemia and therefore even when a genetic disorder is present one should not ignore reversible factors where appropriate treatment can have marked effects on lipid levels. Often secondary factors facilitate the expression of genetic variations to result in an abnormal lipid phenotype. One of the best examples of the interaction of secondary factors and genetic variants is familial dysbetalipoproteinemia ([18-20](#_ENREF_18)). The apolipoprotein E2/E2 polymorphism occurs in approximately 1% of individuals whereas the clinical disorder only occurs in 1-5/5000 and is frequently associated with other disorders, such as obesity, hypothyroidism, and diabetes, which also perturb lipid metabolism. A detailed discussion of the genetic disorders that affect plasma lipid and lipoprotein levels can be found in the individual Endotext chapters that focus on these disorders.

## ORDERING SPECIAL LABORATORY STUDIES

In most circumstances a routine lipid panel consisting of TGs, total cholesterol, HDL-C, and calculated LDL-C and non-HDL-C provides sufficient information to appropriately decide on who to treat and the best treatment approach. In a patient with high fasting TGs (>200-400mg/dl) where the LDL-C cannot be accurately calculated measurement of direct LDL-C may be helpful. However, it should be recognized that there are certain situations where more sophisticated and detailed laboratory studies can be helpful ([21](#_ENREF_21)). Indications for measuring Lp(a) are shown in Table 12 ([21](#_ENREF_21),[22](#_ENREF_22)). Note, it is the opinion of many experts and recommended by some guidelines that Lp(a) should be measured once in all individuals. The various specialized lipid and lipoprotein studies and their appropriate use are discussed in detail in the Endotext chapter “Utility of Advanced Lipoprotein Testing in Clinical Practice” ([21](#_ENREF_21)).

|  |
| --- |
| **Table 12. When to Measure Lp(a) Levels** |
| Patients with premature CHDPatients with a strong family history of premature CHDPatients with a family history of elevated Lp(a) levels (Cascade screening)Patients with resistance to LDL-C lowering with statinsPatients with familial hypercholesterolemiaPatients with aortic valvular stenosis of uncertain causePatients with an unknown cause of ischemic strokePatients with intermediate risk profiles |

Note: It is the opinion of some experts that Lp(a) should be measured once in all individuals

## DECIDING WHO TO TREAT

The purpose of treating lipid disorders is to prevent the development of other diseases, particularly cardiovascular disease. Thus, the decision to treat should be based on the risk of the hyperlipidemia leading to those medical problems. These issues are discussed in detail in the chapters on Risk Assessment and Guidelines for the Management of High Blood Cholesterol and TGs ([23-25](#_ENREF_23)). In addition to cardiovascular complications, marked elevations in TGs can lead to pancreatitis ([23](#_ENREF_23),[26](#_ENREF_26)). The National Lipid Association recommends treating TG levels greater than 500mg/dl while the Endocrine Society recommends treating TGs if they are greater than 1000mg/dl to lower the risk of pancreatitis ([27](#_ENREF_27),[28](#_ENREF_28)).

## GOALS OF THERAPY

The current American College of Cardiology/American Heart Association (ACC/AHA) guidelines do not emphasize specific lipid/lipoprotein goals of therapy but rather to just treat with the statins to lower LDL-C by a certain percentage ([29](#_ENREF_29)). An exception is that they do recommend in patients with very high-risk ASCVD, to use an LDL-C threshold of 70 mg/dL to consider addition of non-statins to statin therapy. In contrast, other groups, such as the National Lipid Association, International Atherosclerosis Society, European Society of Cardiology/European Atherosclerosis Society, and AACE, do recommend lowering the LDL and non-HDL cholesterol levels to below certain levels depending upon the cardiovascular risk in a particular patient but the recommendations from these organizations are not identical ([28](#_ENREF_28),[30-33](#_ENREF_30)).

A detailed discussion of lipid/lipoprotein goals is provided in the chapter on Risk Assessment and Guidelines for the Management of High Blood Cholesterol ([25](#_ENREF_25)). It should be noted that many lipid experts would recommend trying to achieve an LDL-C levels less than 70mg/dl and non-HDL-C levels less than 100mg/dl in patients with cardiovascular disease or patients at very high risk for the development of cardiovascular disease. In other patients, an LDL-C level less than 100mg/dl and non-HDL-C level less than 130mg/dl is a reasonable goal. AACE and European Society of Cardiology/European Atherosclerosis Society have recommended LDL-C levels less than 55mg/dl in patients at very high risk ([30](#_ENREF_30),[31](#_ENREF_31),[33](#_ENREF_33)). With the results of the IMPROVE-IT trial and PCKS9 inhibitor studies, which showed that adding ezetimibe or a PCSK9 inhibitor to statin therapy resulted in an additional decrease in LDL-C levels and a further reduction in cardiovascular events, the arguments in favor of trying to reach lower lipid/lipoprotein goals has been greatly strengthened ([34-36](#_ENREF_34)). Moreover, the results of these and other studies provide strong support that the lower the LDL-C level the greater the reduction in cardiovascular events ([37](#_ENREF_37),[38](#_ENREF_38)).

## TREATMENT TO REDUCE COMPLICATIONS OF DYSLIPIDEMIA

The first priority in treating lipid disorders is to lower the LDL-C levels to goal, unless TGs are markedly elevated (> 500-1000mg/dl), which increases the risk of pancreatitis. LDL-C is the usual first priority because the data linking lowering LDL-C with reducing cardiovascular disease are extremely strong and we now have the ability to markedly decrease LDL-C levels. Dietary therapy is the initial step but in the majority of patients’ dietary modifications will not be sufficient to achieve the LDL-C goals. If patients are willing and able to make major changes in their diet it is possible to achieve remarkable reductions in LDL-C levels but this seldom occurs in clinical practice ([10](#_ENREF_10)). Additionally, the dietary changes need to be sustained for a long period of time to be effective and many patients while able to follow an LDL-C lowering diet in the short term are unable to follow the diet for an extended period of time.

**Primary Prevention Patients**

The first step is determining the risk for developing atherosclerotic cardiovascular disease. There are a number of different calculators for determining risk. In the US the most popular is the ACC/AHA risk calculator) ([29](#_ENREF_29)) or the PREVENT risk calculator ([39](#_ENREF_39)) whereas in Europe the SCORE (Systematic Coronary Risk Estimation) is popular ([31](#_ENREF_31),[40](#_ENREF_40)). The ACC/AHA recommendations are shown in Figure 1 and the European Society of Cardiology/European Atherosclerosis Society recommendations are shown in Figure 2.



**Figure 1. ACC/AHA Recommendations for Patients without ASCVD, Diabetes, or LDL-C greater than 190mg/dl (**[**29**](#_ENREF_29)**). Risk enhancers are listed in table 13. (Note the risk is for MI and stroke, both fatal and nonfatal).**

|  |
| --- |
| **Table 13. ASCVD Risk Enhancers** |
| Family history of premature ASCVDPersistently elevated LDL > 160mg/dl Chronic kidney diseaseMetabolic syndromeHistory of preeclampsiaHistory of premature menopauseInflammatory disease (especially rheumatoid arthritis, psoriasis, HIV)Ethnicity (e.g., South Asian ancestry)Persistently elevated TGs > 175mg/dl Hs-CRP > 2mg/LLp(a) > 50mg/dl or >125nmol/LApo B > 130mg/dlAnkle-brachial index (ABI) < 0.9 |

****

**Figure 2. European Society of Cardiology/European Atherosclerosis Society Recommendations for Primary Prevention Patients (**[**31**](#_ENREF_31)**). Risk categories are shown in table 14 and goals of therapy in Table 15 and 16. (Note that the SCORE risk is for a fatal event). There are different tables for different European countries.**

|  |
| --- |
| **Table 14. Cardiovascular Risk Categories** |
| Very High Risk | ASCVDDM with target organ damage or at least three major risk factors or early onset of T1DM of long duration (>20 years)Severe CKD (eGFR <30 mL/min/1.73 m2)A calculated SCORE >10% for 10-year risk of fatal CVDFH with ASCVD or with another major risk factor |
| High Risk | Markedly elevated single risk factors, in particular TC >310 mg/dL, LDL-C >190 mg/dL, or BP >180/110 mmHgPatients with FH without other major risk factorsPatients with DM without target organ damage with DM duration >10 years or another additional risk factorModerate CKD (eGFR 3059 mL/min/1.73 m2).A calculated SCORE >5% and <10% for 10-year risk of fatal CVD |
| Moderate Risk | Young patients (T1DM <35 years; T2DM <50 years) with DM duration <10 years, without other risk factorsCalculated SCORE >1 % and <5% for 10-year risk of fatal CVD. |
| Low Risk | Calculated SCORE <1% for 10-year risk of fatal CVD |

|  |
| --- |
| **Table 15. ESC/EAS LDL Cholesterol Goals** |
| Very High Risk | LDL-C reduction of >50% from baseline and an LDL-C goal of <1.4 mmol/L (<55 mg/dL) is recommended |
| High Risk | LDL-C reduction of >50% from baseline and an LDL-C goal of <1.8 mmol/L (<70 mg/dL) is recommended |
| Moderate Risk | LDL-C goal of <2.6 mmol/L (<100 mg/dL) should be considered |
| Low Risk | LDL-C goal <3.0 mmol/L (<116 mg/dL) may be considered. |

|  |
| --- |
| **Table 16. ESC/EAS Goals of Therapy** |
|  | **Non-HDL-C** | **Apo B** |
| Very High Risk | <85mg/d; | <65mg/dL |
| High Risk | <100mg/dL | <80mg/dL |
| Moderate Risk | <130mg/dL | <100mg/dL |

A few caveats are worth noting. First, in patients less than 60 years of age it is very helpful to calculate the life-time risk of ASCVD events. Often one will find that the 10-year risk is modest, but the life-time risk is high and this information should be included in the risk discussion to help in the decision process. Second, patients should be made aware of the natural history of ASCVD i.e., that it begins early in life and slowly progresses overtime with high LDL-C levels accelerating the rate of development of atherosclerosis and low LDL-C leading to a slower progression of atherosclerosis ([38](#_ENREF_38),[41](#_ENREF_41)). Third, patients should be made aware of genetic studies demonstrating that variants in genes that lead to lifetime decreases in LDL-C levels (for example the HMG-CoA reductase gene, NPC1L1 gene, PCSK9 gene, ATP citrate lyase gene, and LDL receptor gene) result in a decreased risk of cardiovascular events. In a recent study it was reported that a 10mg/dL lifetime decrease in LDL-C with any of these genetic variants was associated with a 16-18% decrease in cardiovascular events whereas a 10mg/dl reduction in LDL-C with lipid lowering therapy later in life results in only approximately a 5% decrease in cardiovascular events ([37](#_ENREF_37),[42](#_ENREF_42),[43](#_ENREF_43)). The combination of the natural history and the results observed with genetic variants strongly suggests that early therapy to lower LDL-C levels will have greater effects on reducing the risk of ASCVD events than starting therapy later in life. This information needs to be discussed with the patient. Fourth, if the patient or health care provider are uncertain of the best course of action obtaining a cardiac calcium scan can be very helpful in the decision-making process, particularly in older individuals. A score of 0, particularly in an older patient would indicate that statin therapy is not needed whereas a score > 100 would indicate a need for statin therapy ([29](#_ENREF_29)). A score of 1-99 favors the use of a statin ([29](#_ENREF_29)).

In most primary prevention patients, statin therapy is sufficient to lower LDL-C levels to goal (< 100mg/dL or < 70mg/dL depending upon patient’s risk). One can usually start with moderate statin therapy (for example atorvastatin 10-20mg or rosuvastatin 5-10mg) and increase the statin dose, if necessary, to achieve LDL-C goals. Statins are available as generic drugs and therefore are relatively inexpensive. If a patient does not achieve their LDL-C goal on intensive statin therapy, cannot tolerate statin therapy, or is able to take only a low dose of a statin one can use ezetimibe (generic drug), bempedoic acid, bile acid sequestrants, or PCSK9 inhibitors to further lower LDL-C levels (for detailed discussion of cholesterol lowering drugs see ([44](#_ENREF_44))). It should be noted that the addition of ezetimibe or a PCSK9 inhibitor to statin therapy has been shown to reduce cardiovascular events ([34-36](#_ENREF_34)). In most situations, ezetimibe is the drug of choice given its low cost, ability to reduce ASCVD events, and long-term safety record. If LDL-C is not close to goal PCSK9 inhibitors can be used. In patients intolerant of statin therapy bempedoic acid has been shown to reduce cardiovascular disease ([45](#_ENREF_45)). Once LDL-C is at goal if the non-HDL-C remains high one can consider the approaches described in the section describing the approach to patients with LDL-C at goal with elevated TGs.

**Patients with LDL Cholesterol Greater than 190mg/dl**

When the LDL-C is greater than 190mg/dl the patient should be started on intensive statin therapy (atorvastatin 40-80mg per day or rosuvastatin 20-40mg per day). If the LDL-C goal is not achieved (usually < 100mg/dL but if patient is high risk < 70mg/dL) additional lipid lowering medications should be added. If the LDL-C is relatively close to goal one can use ezetimibe but if the LDL-C is far from the goal the use of a PCSK9 inhibitor should be employed. Because of the potential for a genetic disorder, either monogenic or polygenic, one should check family members for lipid abnormalities. If possible genetic testing for monogenic disorders causing hypercholesterolemia is recommended ([46](#_ENREF_46)).

**Patients with Diabetes**

Most patients with diabetes (age 40-75) without risk factors should be started on moderate statin therapy (for example atorvastatin 10-20mg or rosuvastatin 5-10mg). In young individuals (< age 40) and older individuals (> age 75) one needs to use clinical judgment. Patients with diabetes with ASCVD or risk factors should be started on intensive statin therapy. In my opinion reasonable goals are shown in table 17 (similar to AACE and ADA guidelines) ([30](#_ENREF_30),[47](#_ENREF_47)). If intensive statin therapy does not achieve LDL-C goals additional drugs can be added. If reasonably close to the LDL-C goal the initial drug added should be ezetimibe. If far from goal one could add a PCSK9 inhibitor. Once LDL-C is at goal if the non-HDL-C remains high one can consider the approaches described in the section describing the approach to patients with LDL-C at goal with elevated TGs.

|  |
| --- |
| **Table 17. ASCVD Risk Categories and Treatment Goals** |
| **Risk Category** | **Risk Factors/10-year risk** | **LDL-C mg/dl** | **Non-HDL-C mg/dl** |
| Extreme Risk | Diabetes and clinical cardiovascular disease | <55 | <80 |
| Very High Risk | Diabetes with one or more risk factors | <70 | <100 |
| High Risk | Diabetes and no other risk factors | <100 | <130 |

**Secondary Prevention Patients**

Patients with ASCVD (secondary prevention patients) should be started on intensive statin therapy (atorvastatin 40-80mg per day or rosuvastatin 20-40mg per day). Given the extensive data showing that the lower the LDL-C the greater the reduction in ASCVD events most secondary prevention patients would benefit from the addition of ezetimibe to maximize LDL-C lowering without markedly increasing costs ([37](#_ENREF_37),[38](#_ENREF_38)). The goal LDL-C in this patient population at a minimum is an LDL<70mg/dL but many experts and some guidelines would prefer an LDL-C<55mg/dL if possible. If on intensive statin therapy and ezetimibe treatment the LDL-C is far above goal one could consider adding a PCSK9 inhibitor (this is particularly necessary if the LDL-C is greater than 100mg/dL or the patient is at very high risk due to other factors (diabetes, cerebral vascular disease, peripheral vascular disease, recent MI, history of multiple MIs) ([37](#_ENREF_37),[38](#_ENREF_38)).

**Patients with LDL Cholesterol at Goal but High TGs (>150mg/dL to <500mg/dL)**

Patients with an LDL-C at goal but high TG levels (>150mg/dL to <500mg/dL) will often have increased non-HDL-C levels. Numerous studies have shown that the risk of ASCVD events is increased in this patient population ([48](#_ENREF_48)). The initial step should be to improve lifestyle, treat secondary disorders that may be contributing to the increase in TGs, and if possible, discontinue medications that increase TG levels. In the era of statin therapy, it is uncertain whether lowering TG levels in patients on statin therapy will further reduce cardiovascular events. Studies have not demonstrated a reduction in cardiovascular events when niacin is added to statin therapy and given the side effects of niacin enthusiasm for using niacin in combination with statins to reduce ASCVD is limited ([49](#_ENREF_49),[50](#_ENREF_50)). Additionally, the ACCORD-LIPID trial failed to demonstrate that adding fenofibrate to statin therapy ([51](#_ENREF_51)) and the PROMINENT trial failed to demonstrate that adding pemafibrate to statin therapy ([52](#_ENREF_52)) reduces cardiovascular disease. Thus, there is little evidence that adding either niacin or a fibrate to statin therapy will be beneficial in reducing cardiovascular events.

The REDUCE-IT trial demonstrated that adding the omega-3-fatty acid icosapent ethyl (EPA; Vascepa) to statin therapy in patients with elevated TG levels reduced the risk of ASCVD events by 25% while decreasing TG levels by 18% ([53](#_ENREF_53)). Similar results were seen in the JELIS and RESPECT-EPA trials ([54](#_ENREF_54),[55](#_ENREF_55)). In these trials the reduction in TG levels was relatively modest and would not have been expected to result in the magnitude of the decrease in cardiovascular disease observed. Other actions of EPA, such as decreasing platelet function, anti-inflammation, decreasing lipid oxidation, stabilizing membranes, etc. could account for or contribute to the reduction in cardiovascular events ([56](#_ENREF_56)). It should be recognized that the STRENGTH and OMEMI trials using EPA and DHA failed to reduce cardiovascular events despite reducing TG levels to a similar degree as in the REDUCE-IT trial ([57](#_ENREF_57),[58](#_ENREF_58)). Whether EPA has special properties that resulted in the reduction in cardiovascular events in the REDUCE-IT, JELIS, and RESPECT-EPA trials or there were flaws in these trials is debated ([56](#_ENREF_56),[59](#_ENREF_59)). Clinicians will need to balance the potential benefits vs. potential side effects and decide for the individual patient whether to treat with EPA (icosapent ethyl). For a detailed discussion of TG lowering drugs see the Endotext chapter on this topic ([60](#_ENREF_60)).

**Patients with Very High TG Levels (>500-1000mg/dL)**

The main aim is to keep TG levels below 500 mg/dL to prevent TG-induced pancreatitis ([26](#_ENREF_26),[61](#_ENREF_61)).

FAMILIAL HYPERCHYLOMICRONEMIA (FCS)

FCS is a rare autosomal recessive disorder due to an abnormality in the genes listed in table 9 that result in the absence of functional lipoprotein lipase (LPL) activity ([61-63](#_ENREF_61)). Patients with FCS respond poorly to most TG lowering drugs (fibrates, omega-3-fatty acids, niacin) ([61-63](#_ENREF_61)). A very low-fat diet (5-10% of total calories) is the most effective treatment but can be difficult for many patients to comply with ([61-63](#_ENREF_61)). Orlistat has been effective in lowering TG levels ([63](#_ENREF_63)). Apo C-III inhibitors are approved in the US and Europe and lower Apo C-III levels and are very effective in lowering TG levels in patients with FCS ([60](#_ENREF_60),[63](#_ENREF_63)). Additionally, they also reduce episodes of pancreatitis ([60](#_ENREF_60)).

MULTIFACTORIAL CHYLOMICRONEMIA SYNDROME (MCS)

MCS is due to the coexistence of a genetic predisposition (polygenic or heterozygous for genes that cause FCS) for hypertriglyceridemia with 1 or more secondary causes of hypertriglyceridemia (see tables 3 and 4) ([18](#_ENREF_18),[26](#_ENREF_26),[61](#_ENREF_61),[62](#_ENREF_62)). Initial treatment is a very low-fat diet to reduce TG levels into a safe range (<1000mg/dL). Treating secondary disorders that raise TG levels and when possible, stopping drugs that increase TG levels is essential ([18](#_ENREF_18),[26](#_ENREF_26),[61](#_ENREF_61),[62](#_ENREF_62)). If the TG levels remain above 500mg/dL the addition of fenofibrate or omega-3-fatty acids is indicated. Many patients with MCS are at high risk for ASCVD and therefore after TG levels are controlled the patient should be evaluated for cardiovascular disease risk and if indicated statin therapy initiated.

**Patients with High Lp(a) Levels**

Life style changes do not significantly lower Lp(a) levels ([64](#_ENREF_64)). The effect of lipid lowering drugs on Lp(a) levels is shown in Table 18. In patients with elevations in Lp(a) the initial therapy is to aggressively control the other cardiovascular disease risk factors. In some instances, one can use niacin, PCSK9 inhibitors, or in postmenopausal women estrogen to lower Lp(a) levels but the effect of these drugs on preventing cardiovascular events by lowering Lp(a) levels is uncertain ([16](#_ENREF_16),[65](#_ENREF_65)). Studies of an antisense oligonucleotide or small interfering RNA (both not yet approved) directed at apo(a) have shown that these drugs can lower Lp(a) by >75% without effecting other lipoprotein levels ([66](#_ENREF_66),[67](#_ENREF_67)). Lipoprotein apheresis can be employed to lower Lp(a) in patients with very high Lp(a) levels who continue to have cardiovascular events despite optimal medical management ([68](#_ENREF_68)).

|  |
| --- |
| **Table 18. Effect of Lipid Lowering Drugs on Lp(a) Levels** |
| Statins | No Effect or slight increase |
| Ezetimibe | No Effect or slight increase |
| Fibrates | No Effect |
| Niacin | Decrease 15-25%. Greatest decrease in patients with highest Lp(a) levels |
| PCSK9 Inhibitors | Decrease 20-30%  |
| Estrogen | Decrease 20-35% |
| Mipomersen\*\* | Decrease 25-30% |
| Lomitapide\* | Decrease 15-20% |
| Evinacumab | No effect in homozygous familiar hypercholesterolemiaDecrease 16% in refractory hypercholesterolemia |
| CETP Inhibitors\*\* | Decrease ~ 25% |
| Apo (a) antisense and siRNA\*\* | Decrease > 75% |

\*only approved for the treatment of Homozygous FH; \*\*not currently available

**Decreased HDL Cholesterol Levels**

Despite epidemiologic studies consistently showing that high HDL-C levels are associated with a decreased risk of cardiovascular disease there are no studies demonstrating that increasing HDL-C levels reduces cardiovascular disease ([69](#_ENREF_69)). It should be recognized that the crucial issue with HDL may not be the HDL-C levels per se but rather the function of the HDL particles ([69](#_ENREF_69)). Assays have been developed to determine the ability of HDL to facilitate cholesterol efflux from macrophages and these studies have shown that the levels of HDL-C do not necessarily indicate the ability to mediate cholesterol efflux ([70](#_ENREF_70)). Similarly, the ability of HDL to protect LDL from oxidation may also play an important role in the ability of HDL to reduce ASCVD ([71](#_ENREF_71)). Thus, the functional capability of HDL may be more important than HDL-C levels ([69-71](#_ENREF_69)).

**CONCLUSION**

In summary, modern therapy demands that we aggressively evaluate and when indicated treat lipid disorders to reduce the risk of atherosclerotic cardiovascular disease and in those with very high TGs to reduce the risk of pancreatitis.

**ACKNOWKEDGEMENTS**

This work was supported by grants from the Northern California Institute for Research and Education.

## REFERENCES

1. Shapiro MD, Feingold KR. Monogenic Disorders Causing Hypobetalipoproteinemia. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2024.

2. Shapiro MD, Feingold KR. Monogenic Disorders Altering HDL Levels. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2024.

3. Feingold KR. The Effect of Endocrine Disorders on Lipids and Lipoproteins. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2023.

4. Feingold KR. Dyslipidemia in Patients with Diabetes. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2023.

5. Herink M, Ito MK. Medication Induced Changes in Lipid and Lipoproteins. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2018.

6. Lacount S, Tannock LR. Dyslipidemia in Chronic Kidney Disease. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2025.

7. Feingold KR. Obesity and Dyslipidemia. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2023.

8. Feingold KR, Grunfeld C. The Effect of Inflammation and Infection on Lipids and Lipoproteins. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2025.

9. Sarkar S, Brown TT. Lipid Disorders in People with HIV. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2023.

10. Feingold KR. The Effect of Diet on Cardiovascular Disease and Lipid and Lipoprotein Levels. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2024.

11. Patni N, Ahmad Z, Wilson DP. Genetics and Dyslipidemia. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2023.

12. Levenson AE, de Ferranti SD. Familial Hypercholesterolemia. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2023.

13. McNeal CJ, Peterson AL. Lipoprotein (a) in Youth. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2023.

14. Warden BA, Fazio S, Shapiro MD. Familial Hypercholesterolemia: Genes and Beyond. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2024.

15. Hegele RA, Boren J, Ginsberg HN, Arca M, Averna M, Binder CJ, Calabresi L, Chapman MJ, Cuchel M, von Eckardstein A, Frikke-Schmidt R, Gaudet D, Hovingh GK, Kronenberg F, Lutjohann D, Parhofer KG, Raal FJ, Ray KK, Remaley AT, Stock JK, Stroes ES, Tokgozoglu L, Catapano AL. Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. Lancet Diabetes Endocrinol 2020; 8:50-67

16. Khovidhunkit W. Lipoprotein(a). In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2023.

17. Dron JS, Hegele RA. Polygenic influences on dyslipidemias. Curr Opin Lipidol 2018; 29:133-143

18. Subramanian S. Hypertriglyceridemia: Pathophysiology, Role of Genetics, Consequences, and Treatment. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2024.

19. Khovidhunkit W. Dysbetalipoproteinemia (Type 3 Hyperlipoproteinemia). In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2025.

20. Shah AS, Wilson DP. Genetic Disorders Causing Hypertriglyceridemia in Children and Adolescents. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2023.

21. Feingold KR. Utility of Advanced Lipoprotein Testing in Clinical Practice. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2023.

22. Wilson DP, Jacobson TA, Jones PH, Koschinsky ML, McNeal CJ, Nordestgaard BG, Orringer CE. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol 2022; 16:e77-e95

23. Messersmith A, Purbey R, Tannock LR. Risk of Fasting and Non-Fasting Hypertriglyceridemia in Coronary Vascular Disease and Pancreatitis. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2025.

24. Daniels SR. Guidelines for Screening, Prevention, Diagnosis and Treatment of Dyslipidemia in Children and Adolescents. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2023.

25. Feingold KR. Guidelines for the Management of High Blood Cholesterol. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2025.

26. Feingold KR. Pancreatitis Secondary to Hypertriglyceridemia. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2022.

27. Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH, Stalenhoef AF, Endocrine s. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012; 97:2969-2989

28. Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, McKenney JM, Grundy SM, Gill EA, Wild RA, Wilson DP, Brown WV. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. J Clin Lipidol 2014; 8:473-488

29. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC, Jr., Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139:e1082-e1143

30. Handelsman Y, Jellinger PS, Guerin CK, Bloomgarden ZT, Brinton EA, Budoff MJ, Davidson MH, Einhorn D, Fazio S, Fonseca VA, Garber AJ, Grunberger G, Krauss RM, Mechanick JI, Rosenblit PD, Smith DA, Wyne KL. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary. Endocr Pract 2020; 26:1196-1224

31. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O, Group ESCSD. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41:111-188

32. Expert Panel on Dyslipidemia. An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia: executive summary. Atherosclerosis 2014; 232:410-413

33. Patel SB, Wyne KL, Afreen S, Belalcazar LM, Bird MD, Coles S, Marrs JC, Peng CC, Pulipati VP, Sultan S, Zilbermint M. American Association of Clinical Endocrinology Clinical Practice Guideline on Pharmacologic Management of Adults With Dyslipidemia. Endocr Pract 2025; 31:236-262

34. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM, Improve-It Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015; 372:2387-2397

35. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, Fourier Steering Committee Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017; 376:1713-1722

36. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM, Odyssey Outcomes Committees Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med 2018; 379:2097-2107

37. Feingold KR. Maximizing the benefits of cholesterol-lowering drugs. Curr Opin Lipidol 2019; 30:388-394

38. Feingold KR, Chait A. Approach to patients with elevated low-density lipoprotein cholesterol levels. Best Pract Res Clin Endocrinol Metab 2022:101658

39. Khan SS, Matsushita K, Sang Y, Ballew SH, Grams ME, Surapaneni A, Blaha MJ, Carson AP, Chang AR, Ciemins E, Go AS, Gutierrez OM, Hwang SJ, Jassal SK, Kovesdy CP, Lloyd-Jones DM, Shlipak MG, Palaniappan LP, Sperling L, Virani SS, Tuttle K, Neeland IJ, Chow SL, Rangaswami J, Pencina MJ, Ndumele CE, Coresh J, Chronic Kidney Disease Prognosis Consortium, the American Heart Association Cardiovascular-Kidney-Metabolic Science Advisory Group. Development and Validation of the American Heart Association's PREVENT Equations. Circulation 2024; 149:430-449

40. Score working group E. S. C. Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J 2021; 42:2439-2454

41. Wilson DP. Is Atherosclerosis a Pediatric Disease? In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2023.

42. Ference BA, Ray KK, Catapano AL, Ference TB, Burgess S, Neff DR, Oliver-Williams C, Wood AM, Butterworth AS, Di Angelantonio E, Danesh J, Kastelein JJP, Nicholls SJ. Mendelian Randomization Study of ACLY and Cardiovascular Disease. N Engl J Med 2019; 380:1033-1042

43. Cholesterol Treatment Trialists Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376:1670-1681

44. Feingold KR. Cholesterol Lowering Drugs. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2024.

45. Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, Thompson PD, Libby P, Cho L, Plutzky J, Bays HE, Moriarty PM, Menon V, Grobbee DE, Louie MJ, Chen CF, Li N, Bloedon L, Robinson P, Horner M, Sasiela WJ, McCluskey J, Davey D, Fajardo-Campos P, Petrovic P, Fedacko J, Zmuda W, Lukyanov Y, Nicholls SJ, Clear Outcomes Investigators. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med 2023; 388:1353-1364

46. Berberich AJ, Hegele RA. Genetic testing in dyslipidaemia: An approach based on clinical experience. Best Pract Res Clin Endocrinol Metab 2022:101720

47. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Das SR, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Kosiborod M, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA, on behalf of the American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023. Diabetes Care 2023; 46:S158-S190

48. Sandesara PB, Virani SS, Fazio S, Shapiro MD. The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk. Endocr Rev 2019; 40:537-557

49. Hps Thrive Collaborative Group, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, Armitage J. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014; 371:203-212

50. AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365:2255-2267

51. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR, 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC, Jr., Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362:1563-1574

52. Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Pall D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM, Prominent Investigators. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med 2022; 387:1923-1934

53. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Jr., Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM, Reduce-It Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019; 380:11-22

54. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Japan, E. P. A. lipid intervention study Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007; 369:1090-1098

55. Miyauchi K, Iwata H, Nishizaki Y, Inoue T, Hirayama A, Kimura K, Ozaki Y, Murohara T, Ueshima K, Kuwabara Y, Tanaka-Mizuno S, Yanagisawa N, Sato T, Daida H, Respect-Epa Investigators. Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid (RESPECT-EPA). Circulation 2024; 150:425-434

56. Mason RP, Sherratt SCR, Eckel RH. Omega-3-fatty acids: Do they prevent cardiovascular disease? Best Pract Res Clin Endocrinol Metab 2022:101681

57. Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, McGuire DK, Mozaffarian D, Ridker PM, Ray KK, Katona BG, Himmelmann A, Loss LE, Rensfeldt M, Lundstrom T, Agrawal R, Menon V, Wolski K, Nissen SE. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA 2020; 324:2268-2280

58. Kalstad AA, Myhre PL, Laake K, Tveit SH, Schmidt EB, Smith P, Nilsen DWT, Tveit A, Fagerland MW, Solheim S, Seljeflot I, Arnesen H, Omemi Investigators. Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction: A Randomized, Controlled Trial. Circulation 2021; 143:528-539

59. Goff ZD, Nissen SE. N-3 polyunsaturated fatty acids for cardiovascular risk. Curr Opin Cardiol 2022; 37:356-363

60. Feingold KR. Triglyceride Lowering Drugs. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, . eds. Endotext. South Dartmouth (MA)2025.

61. Chait A, Feingold KR. Approach to patients with hypertriglyceridemia. Best Pract Res Clin Endocrinol Metab 2022:101659

62. Chait A, Eckel RH. The Chylomicronemia Syndrome Is Most Often Multifactorial: A Narrative Review of Causes and Treatment. Ann Intern Med 2019; 170:626-634

63. Javed F, Hegele RA, Garg A, Patni N, Gaudet D, Williams L, Khan M, Li Q, Ahmad Z. Familial chylomicronemia syndrome: An expert clinical review from the National Lipid Association. J Clin Lipidol 2025;

64. Enkhmaa B, Anuurad E, Berglund L. Lipoprotein (a): impact by ethnicity and environmental and medical conditions. J Lipid Res 2016; 57:1111-1125

65. van Capelleveen JC, van der Valk FM, Stroes ES. Current therapies for lowering lipoprotein (a). J Lipid Res 2016; 57:1612-1618

66. Wei T, Cho L. Recent lipoprotein(a) trials. Curr Opin Lipidol 2022; 33:301-308

67. Jean-Gilles M, Gencer B. Therapeutic advances in the Lp(a) battle: what do we know and what are the most awaited novelties in the field? Curr Opin Lipidol 2025; 36:130-137

68. Feingold KR. Lipoprotein Apheresis. In: Feingold KR, Ahmed SF, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2023.

69. Thomas SR, Zhang Y, Rye KA. The pleiotropic effects of high-density lipoproteins and apolipoprotein A-I. Best Pract Res Clin Endocrinol Metab 2022:101689

70. Hovingh GK, Rader DJ, Hegele RA. HDL re-examined. Curr Opin Lipidol 2015; 26:127-132

71. Navab M, Reddy ST, Van Lenten BJ, Anantharamaiah GM, Fogelman AM. The role of dysfunctional HDL in atherosclerosis. J Lipid Res 2009; 50 Suppl:S145-149